Atopaxar

A potent, reversible PAR-1 antagonist with IC50 of 19 nM; shows potent inhibitory effects on human platelet aggregation induced by thrombin and TRAP with IC50 of 64 nM and 31 nM, respectively, with no effect on platelet aggregation induced by either ADP or collagen; inhibits arterial thrombosis without affecting bleeding time in photochemically-induced thrombosis model guinea pigs.Thrombosis Phase 2 Clinical (In Vitro) :Atopaxar (0.0001-10 μM; 1h) inhibits haTRAP (high-affinity thrombin receptor activating peptide) binding to PAR-1 on human platelet membranes in a concentration-dependent manner, with an IC50 of 0.019 μM.Atopaxar inhibits human platelet aggregation induced by thrombin or TRAP in a concentration-dependent manner.Atopaxar does not inhibit PRP (platelet-rich plasma) aggregation induced by ADP, U46619, collagen, and PAR-4ap, up to a concentration of 20 μM. (In Vivo) :Atopaxar (30-100 mg/kg; p.o.) causes a dose-dependent prolongation of the time to occlusion of the femoral artery in photochemically-induced thrombosis (PIT) guinea pigs model.Atopaxar does not prolong bleeding time in guinea pigs at the highest tested dosage of 1000 mg/kg.

751475-53-3

E-5555 | E5555

>98% (HPLC)

In Vitro: DMSO : 50 mg/mL (94.76 mM)

COC1=C (N2CCOCC2) C=C (C (CN (CC3=C4C (F) =C (OCC) C (OCC) =C3) C4=N) =O) C=C1C (C) (C) C

C29H38FN3O5

527.6374

Storage temperature: -20°C. Stability: ≥ 2 years

For research use only.